The vaccine uses mRNA technology similar to the COVID-19 vaccine. Patients undergo surgery to remove the tumor, which is then sequenced to make a personalized vaccine specific to the patient’s cancer. The vaccine is developed in four to six weeks while patients recover from surgery. Patients receive six weekly injections, and following six months of standard chemotherapy, patients receive six more vaccines as boosters.
In the phase 1 trial of 32 patients, 25% of recipients were in complete remission from pancreatic cancer, Davendra Sohal, MD, site principal investigator, said in a Feb. 20 system press release.
The new trial aims to enroll 260 patients globally. The vaccine reportedly had minimal side effects, including mild aches, chills and mild fever.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
